Curis Revenue and Competitors

Boston, MA USA

Location

$69M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Curis's estimated annual revenue is currently $15M per year.(i)
  • Curis's estimated revenue per employee is $81,522
  • Curis's total funding is $69M.

Employee Data

  • Curis has 184 Employees.(i)
  • Curis grew their employee count by -16% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.2M10%N/AN/A
#3
$4.2M2735%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$1.4M929%N/AN/A
#6
$235M255-31%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.3M340%N/AN/A
#10
$1.9M12-8%N/AN/A
Add Company

Curis, Inc. is generating therapies that regulate the pathways used by the body to maintain and restore health. The company focuses on signaling pathways that govern the proliferation and differentiation of cells. These same pathways control maintenance, repair, and regeneration of tissues and organs from infancy through old age. This approach has created an approved product for bone regeneration and enables Curis to build a portfolio of product candidates in neurology, kidney disease, and cancer.

keywords:Biotechnology

$69M

Total Funding

184

Number of Employees

$15M

Revenue (est)

-16%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Curis News

2022-03-30 - FDA puts Curis' leukemia trial on partial hold after patient death ...

The list of biotechs under clinical hold keeps getting longer. Curis is the latest company to join the list, with the FDA slapping a partial hold on a phase...

2022-03-30 - FDA places partial hold on Curis cancer drug after patient death in ...

The open-label Phase 1/2 clinical trial of the Curis drug is a dose-escalation study enrolling patients with acute myeloid leukemia (AML) or...

2022-03-30 - Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia ...

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into...

2021-10-07 - Curis : Announces New Preclinical Data Highlighting the Potential of CA-4948 in Multiple Hematologic Malignancies Presented at the AACR-NCI-EORTC Virtual Conference on Molecular Targets and Cancer Therapeutics

LEXINGTON, Mass., Oct. 7, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced two poster presentations with new preclinical data for CA-4948, a first-in-class small molecule IR ...

2021-08-03 - Curis Reports Second Quarter 2021 Financial Results

LEXINGTON, Mass., Aug. 3, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the second quarter ended June 30, 2021. "In the second quarter of 2021 ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15M185-2%N/A
#2
$7.5M18618%N/A
#3
$15M1887%N/A
#4
$15M1893%N/A
#5
$75M1901%N/A

Curis Executives


NameTitle
James DentzerPresident & CEO
Diantha DuvallChief Financial Officer
James DentzerPresident & CEO
Reinhard RoemelingSenior Vice President, Clinical Development
Christine GuertinVice President of Regulatory Affairs and Quality Assurance
Raul SoikesVice President Portfolio Management
Mark NoelVP - Technology Management and Intellectual Property
Marissa VolpeVice President Clinical Operations
Reinhard RoemelingSenior Vice President and Head of Clinical Development
Li ZhouVP, Head of Biostatistics and Data Management
Dora FerrariVP, Clinical Operations
Felix GeisslerVP, Medical Affairs